Human Challenge Study to Evaluate the Efficacy of MV-012-968 Vaccine

Summary

The purpose of this research study is to evaluate whether the investigational, live attenuated, intranasally delivered vaccine MV-012-968 ('study vaccine') may have prophylactic efficacy against symptomatic RSV infection when administered to adults 18-45 years of age in the Human Viral Challenge model.

Timeline

Start

2020-12-29

Primary completion

2021-05-07

Completion

2021-09-09

Drugs

Indications